Journal of Pharmacy & Pharmaceutics
Current Concept And Future Perspectives On Study Of Diabetes Neuropathy
Department of pharmaceutics, JSS College of pharmacy, JSS University Mysore, India
D. Nagasamy Venkatesh, Department of Pharmaceutics, JSS College of Pharmacy, Ooty, Nilgiris-643001, Tamil Nadu, India, E-mail: firstname.lastname@example.org
Venkatesh, D.N., et al. Current Concept and Future Perspectives on Study of Diabetes Neuropathy. (2017) J Pharm Pharmaceutics 4(1): 123- 127.
© 2017 Venkatesh, D.N. This is an Open access article distributed under the terms of Creative Commons Attribution 4.0 International License.
KeywordsNeuropathy; Diabetes mellitus; Pathogenic; Pregabalin
Diabetic neuropathy (DN) is a major cause for blindness. Worldwide it accounts for one type of blindness in the developing country. We have deal with modifying risk factors, genetics, and treatment of DN. Special focus is placed on the rationale and effectiveness of therapeutic modalities, both current and future. Diabetic neuropathy (DN) is a debilitating consequence of diabetes that may be present in as many as one in five patients with diabetes. The objective assessment of DN is difficult, making it challenging to diagnose and assess in both clinical practice and clinical trials. No single treatment exists to prevent or reverse neuropathic changes or to provide total pain relief. Treatment of DN is based on three major approaches: intensive glycemic control, risk factor management and also correlate with genetics configuration where amitriptyline and duloxetine used as antidepressants for pain relief in DN. There is a growing need for studies to evaluate the most potent drugs or combinations for the management of DN to maximize pain relief and improve quality of life. A number of agents are potential candidates for future use in DN therapy, including Nav 1.7 antagonists, N-type calcium channel blockers, NGF antibodies and angiotensin II type 2 receptor antagonists.